Phase II trials with toremifene in advanced breast cancer: A review
- 1 August 1990
- journal article
- review article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 16 (1) , S31-5
- https://doi.org/10.1007/bf01807142
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer an ongoing phase II multicenter Finnish-Latvian cooperative studyBreast Cancer Research and Treatment, 1990
- Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the ratJournal of Steroid Biochemistry, 1990
- ANTIESTROGENIC ACTION OF TOREMIFENE ON HORMONE-DEPENDENT, HORMONE-INDEPENDENT, AND HETEROGENEOUS BREAST-TUMOR GROWTH IN THE ATHYMIC MOUSE1989
- Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor modelEuropean Journal of Cancer and Clinical Oncology, 1988
- The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breastEuropean Journal of Cancer and Clinical Oncology, 1988
- Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II studyEuropean Journal of Cancer and Clinical Oncology, 1988
- ALTERNATIVE MECHANISM OF ACTION OF "ANTI-OESTROGENS" IN BREAST CANCERThe Lancet, 1987
- ANTIOESTROGEN THERAPY OF PURE MESENCHYMAL TUMOURThe Lancet, 1987
- A new triphenylethylene compound, Fc-1157aCancer Chemotherapy and Pharmacology, 1986
- A new triphenylethylene compound, Fc-1157aCancer Chemotherapy and Pharmacology, 1986